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Objectives. The purpose of this study was to assess the efficacy
of attenuation-corrected (AC) technetium-99m (99mTc)-
tetrofosmin single-photon emission computed tomography
(SPECT) in detecting viable myocardium compared to 18F-
fluorodeoxyglucose (FDG) positron emission tomography (PET).
Background. The role of 99mTc-labeled perfusion tracers in the
assessment of myocardial viability remains controversial. Atten-
uation artifacts affect the diagnostic accuracy of SPECT images.
Methods. Twenty-four patients with coronary artery disease
(mean left ventricular ejection fraction 30%) underwent resting
99mTc-tetrofosmin SPECT and FDG PET imaging. Both AC and
non–attenuation-corrected (NC) SPECT images were generated.
Results. Using a 50% threshold for viability by FDG PET, the
percentage of concordant segments of viability between 99mTc-
tetrofosmin and FDG on the patient basis increased from 79.8% 6
14.0% (mean 6 SD) on the NC images to 90.8% 6 10.6% on the
AC images (p 5 0.002). The percentage of 99mTc-tetrofosmin
defect segments within PET-viable segments, an estimate for the
degree of underestimation of viability, decreased from 19.8% 6
15.2% on the NC images to 9.7% 6 12.6% on the AC images (p 5
0.01). Similar results were obtained when a 60% threshold was
used to define viability by FDG PET. When the anterior-lateral
and inferior-septal regions were separately analyzed, the effect of
attenuation correction was significant only in the inferior-septal
region.
Conclusions. The results indicate that AC 99mTc-tetrofosmin
SPECT improves the detection of viable myocardium mainly by
decreasing the underestimation of viability particularly in the
inferior-septal region, although some underestimation/
overestimation of viability may still occur even with attenuation
correction.
(J Am Coll Cardiol 1998;32:927–35)
©1998 by the American College of Cardiology
Myocardial viability assessment represents an important clini-
cal issue in patients with coronary artery disease (CAD) and
severe left ventricular (LV) dysfunction in deciding whether to
proceed with revascularization (1). Viable myocardial areas
are likely to benefit from revascularization, whereas revascu-
larization of scarred myocardium will not lead to an improve-
ment in contractile function. A number of studies have shown
that metabolic imaging with positron emission tomography
(PET) and 18F-fluorodeoxyglucose (FDG) is an accurate non-
invasive diagnostic tool to distinguish viable from scarred
myocardium (2–6). Availability and high cost, however, limit
the wide clinical use of PET imaging. Therefore, efforts have
been made to assess the efficacy of single-photon emission
computed tomography (SPECT) to identify viable myocardium
(7).
Thallium-201 (201Tl) myocardial imaging using either a
reinjection (8,9) or rest-redistribution (10) protocol is a well-
accepted diagnostic technique for the evaluation of myocardial
viability. However, despite the excellent physiologic character-
istics of 201Tl for assessing viability, its low photon energy of 68
to 80 keV and its relatively long half-life pose limitations.
Recently, cationic lipophilic technetium-99m (99mTc)-labeled
perfusion tracers such as 99mTc-sestamibi (11) and 99mTc-
tetrofosmin (12) have been introduced as an alternative to
201Tl, and their utility in assessing myocardial viability, partic-
ularly using a quantitative analysis of regional tracer activity,
has been reported (13–18). The use of 99mTc-labeled perfusion
agents as a viability marker, however, has been questioned by
several studies (14,19–21) in which an underestimation of
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viable myocardium by 99mTc-labeled perfusion agents has been
observed, particularly when compared to FDG PET. Notably,
a recent study has shown that underestimation of viable
myocardium occurred predominantly in the inferior wall (22),
suggesting that the known attenuation of single-photon emit-
ting tracers on conventional SPECT images may play an
important role in such underestimation.
Recently, approaches for attenuation correction have been
proposed (23,24) and clinical results have shown its utility to
improve the detection of CAD (25). We have developed a
system for simultaneous transmission/emission measurement
using a triple-head SPECT system with an off-set fan beam
collimator and Americium 241 (241Am) line source (26,27).
We hypothesized that the use of attenuation correction would
improve the detection of viable myocardium by SPECT tech-
niques.
This study was therefore designed to assess the efficacy of
attenuation-corrected (AC) resting 99mTc-tetrofosmin SPECT
for the detection of viable myocardium using FDG PET as the
reference method for assessing tissue viability.
Methods
Patients. The study population consisted of 25 patients
with angiographically proved CAD and impaired regional or
global LV function. There were 21 men and 3 women with a
mean age of 61 years (range from 48 to 82 years). All but two
patients had a history of prior myocardial infarction (12
anterior wall infarctions, 4 inferior wall infarctions and 7
anterior and inferior wall infarctions). The inclusion criteria of
this study were subnormal left ventricular ejection fraction
(LVEF) (,45%) and/or severe regional left ventricular dys-
function (akinesis or dyskinesis). The mean LVEF, which was
obtained in 23 of 25 patients by contrast left ventriculography
(n 5 21) or radionuclide ventriculography (n 5 2), was 30% 6
11%, ranging from 13% to 65%. The remaining two patients,
in whom LVEF was not measured, had akinetic regions in their
infarct-related arterial territories as assessed by left ventricu-
lography. We studied only patients with stable CAD; patients
with recent myocardial infarction (#1 month) were excluded.
Two patients had previously undergone revascularization. All
but one patient underwent resting 99mTc-tetrofosmin SPECT
with simultaneous transmission/emission scan followed by PET
imaging with FDG on a single day; in the remaining one
patient, PET imaging was performed two days after 99mTc-
tetrofosmin SPECT imaging. All patients continued their
cardiac medications during the radionuclide studies.
Coronary artery disease was defined as $50% reduction in
the luminal diameter of at least one major epicardial coronary
artery as determined by coronary angiography. Twenty patients
had significant stenoses of three vessels, three patients of two
vessels and two patients of one vessel (mean 2.7 vessels per
patient). All patients gave informed consent in accordance
with the institutional Human Clinical Study Committee.
Rest 99mTc-tetrofosmin imaging. After an overnight fast,
each patient was injected with 370 MBq of 99mTc-tetrofosmin
at rest. Simultaneous transmission/emission scanning was
started 40 min after injection using the SPECT system as
described below.
Simultaneous transmission/emission scan. Simultaneous
transmission/emission imaging was performed in a manner as
previously described (26,27), using a triple-head SPECT sys-
tem (MULTISPECT 3, Siemens AG, Erlangen, Germany)
equipped with a low-energy, fan-beam collimator with a focal
length of 53 cm with its focal line offset by 17 cm for detector
1 and with low-energy, high-resolution, parallel-hole collima-
tors for detector 2 and 3. The transmission line source con-
sisted of a 5.55 GBq (150 mCi) 241Am line source sealed in a
stainless-steel tube.
Transmission and emission projection data were acquired
in 64 3 64 matrices. Images were acquired in 6° steps over 360°
for 20 s/projection. An energy window of 59.0 6 5.9 keV was
used for the 241Am transmission photons and a 15% window
centered on the 140 keV peak was used for the emission data.
An 80-s transmission “blank” scan was acquired to compute
attenuation maps from the transmission data.
Processing of SPECT data. Image reconstruction of
SPECT data was performed in a manner similar to that
previously reported by Ficaro et al. (25) except for the use of
filtered back projection to reconstruct transmission data
(26,27). The geometry used in the current study provided a
transmission imaging field of view of 39 cm, yielding little
truncation of the transmission data compared to symmetrical
geometry. The attenuation maps were smoothed using a
Gaussian function with a 2-pixels (14 mm) full-width half-
maximum. The AC emission images were reconstructed using
an iterative reconstruction method (penalized weighted least
squares algorithm [28]) with reconstructed attenuation maps to
correct the emission data for photon attenuation. The non–
attenuation-corrected (NC) emission images were recon-
structed using filtered back projection with a Butterworth filter
of order 5 with a frequency cutoff of 0.25 cycles/pixel.
Positron emission tomography. Attenuation-corrected
static PET images with FDG were acquired 40 min after
injection of 370 MBq of FDG using either ECAT 951R/31
(n 5 9) or ECAT 921/47 (n 5 16) (CTI/Siemens AG,
Knoxville, Tennessee). In-plane spatial resolution was 6 mm
full-width half maximum for both scanners. In subjects without
diabetes mellitus, FDG injection was conducted after an oral
glucose load. Short-acting insulin was administered in known
or suspected diabetic subjects with hyperglycemia to enhance
Abbreviations and Acronyms
AC 5 attenuation-corrected
CAD 5 coronary artery disease
FDG 5 18F-fluorodeoxyglucose
LV 5 left ventricular
NC 5 non–attenuation-corrected
PET 5 positron emission tomography
SPECT 5 single-photon emission computed tomography
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myocardial uptake of FDG as previously described (5). A
transmission scan was acquired for 20 min using three retract-
able 68Ge/68Ga rod sources. Static PET imaging lasting for
20 min was started 40 min after the injection of FDG.
The transaxial data were reconstructed in a 128 3 128 pixel
matrix using a Hanning filter with a cutoff frequency of 0.3
cycles/pixel. The reconstructed transaxial images were trans-
ferred to the same workstations used for processing the
SPECT data.
Data analysis. Image data analysis was performed using a
semiquantitative polar map approach for both SPECT and
PET data, which was developed in our laboratory. This method
involved two steps: 1) the long axis of the left ventricle was
defined interactively in three dimensions; 2) an automatic
volumetric radial search for activity maxima was performed.
The LV myocardium was then divided into apical, anterior,
septal, lateral and inferior regions. Each of the anterior, septal,
lateral and inferior regions was further divided into distal and
basal segments, resulting in nine segments per patient. The
SPECT images were normalized to the pixel showing maximal
value in the LV myocardium. A segment was considered to
have a 99mTc-tetrofosmin defect if the mean regional activity
was ,50% of peak activity. The use of 50% of peak activity to
define a defect as a threshold cutoff for viability by 99mTc-
tetrofosmin was derived from previous literature using this
tracer for assessing myocardial viability (15,18). The regional
FDG uptake was normalized to the region with the maximal
99mTc-tetrofosmin uptake on the AC images. A segment was
considered viable if the normalized regional FDG activity was
$50% or $60% of the reference region; a segment was
considered nonviable if the normalized regional FDG activity
was ,50% or ,60% of the reference region (9,20,21,29,30).
Statistical analysis. Data were expressed as mean 6 SD.
Because the behavior of different segments within a given
patient is not independent, patients were used as the unit of
analysis. For this purpose, we calculated the following three
parameters for an individual patient: 1) the percentage of
concordant segments regarding viability between 99mTc-
tetrofosmin SPECT and FDG PET; 2) the percentage of
99mTc-tetrofosmin defect segments (,50% of peak activity)
within viable segments by FDG PET; 3) the percentage of
99mTc-tetrofosmin uptake segments ($50% of peak) within
nonviable segments. The percentage of concordant segments
should give an estimate of diagnostic accuracy of 99mTc-
tetrofosmin SPECT to detect viable myocardium for a given
patient. The percentage of 99mTc-tetrofosmin defect segments
within PET viable segments, on the other hand, should give an
estimate for the degree of underestimation of viability by
99mTc-tetrofosmin, whereas the percentage of 99mTc-
tetrofosmin uptake segments within PET nonviable segments
should give an estimate for the degree of overestimation of
viability by 99mTc-tetrofosmin. A Wilcoxon signed-rank test
was used to compare mean values between the NC and AC
images. Statistical significance was defined as p , 0.05.
Results
Of 25 patients, one was considered to have an inadequate
FDG study due to poor image quality and was excluded from
further analysis. The remaining 24 patients had FDG images of
diagnostic quality and were considered to be eligible for the
study.
Comparison of activities between 99mTc-tetrofosmin and
FDG. Figure 1 displays NC and AC 99mTc-tetrofosmin SPECT
images as well as corresponding FDG PET images from a
patient with three-vessel CAD and LV dysfunction. The NC
99mTc-tetrofosmin SPECT images show defects in the apex and
inferior wall. The AC images reveal 99mTc-tetrofosmin activity
in the inferior wall, while the apical wall still shows a defect,
suggesting the presence of viable myocardium in the inferior
wall. The FDG PET images confirm the presence of viable
myocardium in that region. The transmission images show
there was no truncation with the SPECT system used in this
study.
Percentage of viable myocardium in relation to 99mTc-
tetrofosmin activity is shown in Table 1. All 216 segments were
evaluable on both NC and AC images. Of a total of 216
segments, 201 (93%) and 182 (84%) segments, respectively,
were viable using 50% and 60% thresholds to define viability
by FDG PET. Most of the segments with preserved 99mTc-
tetrofosmin activity ($70% of peak activity) on both NC and
AC images showed evidence of tissue viability by FDG PET
regardless of the cutoff value applied. Conversely, none of the
segments with very low 99mTc-tetrofosmin activity (,30% of
peak activity) showed evidence of tissue viability. On the other
hand, segments with mildly (50% to 70% of peak) to severely
(30% to 50% of peak) reduced 99mTc-tetrofosmin activity
showed various patterns of tissue viability.
All segments. Figure 2 shows the percentages of concordant
segments regarding viability between 99mTc-tetrofosmin
SPECT and FDG PET, the percentages of 99mTc-tetrofosmin
defect segments within PET viable segments and the percent-
ages of 99mTc-tetrofosmin uptake segments within PET non-
viable segments on the patient basis from a total of 216
segments. Using a 50% threshold for viability by FDG PET,
the percentage of concordant segments of viability between
99mTc-tetrofosmin SPECT and FDG PET, an estimate of
diagnostic accuracy of 99mTc-tetrofosmin SPECT for the de-
tection of viable myocardium, significantly increased from
79.8% 6 14.0% on the NC images to 90.8% 6 10.6% on the
AC images (p 5 0.002). The percentage of 99mTc-tetrofosmin
defect segments within viable segments, an estimate for the
degree of underestimation of viability by 99mTc-tetrofosmin,
decreased from 19.8% 6 15.2% on the NC images to 9.7% 6
12.6% on the AC images (p 5 0.01). The percentage of
99mTc-tetrofosmin uptake segments within PET nonviable
segments, an estimate for the degree of overestimation of
viability by 99mTc-tetrofosmin, tended to decrease from
35.2% 6 44.5% on the NC images to 3.7% 6 11.0% on the AC
images, but with marginal statistical significance (p 5 0.066)
because of the high standard deviation and low patient number
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included in this analysis; only 9 of 24 patients had nonviable
segments based on FDG activity. Similar results were obtained
when a 60% threshold was used to define viability by FDG
PET. The percentage of concordant segments between 99mTc-
tetrofosmin and FDG increased from 83.0% 6 12.1% on the
NC images to 90.3% 6 13.3% on the AC images (p 5 0.028).
The percentage of 99mTc-tetrofosmin defect segments within
viable segments decreased from 14.1% 6 13.5% on the NC
images to 5.7% 6 8.0% on the AC images (p 5 0.014). The
percentages of 99mTc-tetrofosmin uptake segments within PET
nonviable segments, on the other hand, did not differ signifi-
cantly between the NC and AC images (41.0% 6 41.4% vs.
25.6% 6 34.3%, respectively, p 5 0.357). Thus, attenuation
correction improved the concordance of viability between
99mTc-tetrofosmin SPECT and FDG PET, and decreased the
underestimation of viability by 99mTc-tetrofosmin. Addition-
ally, there was a trend towards improved overestimation of
viability by attenuation correction. However, some underesti-
mation and/or overestimation of viability by 99mTc-tetrofosmin
still occurred even on the AC images.
Segments with abnormal wall motion. Regional wall motion
was abnormal in the majority of segments in this patient
population. Fifty segments in 15 patients had normal wall
Figure 1. An 82-year-old man with three-
vessel coronary artery disease. (A) The
non–at tenuat ion-correc ted 9 9 m Tc-
tetrofosmin images (left), attenuation-
corrected 99mTc-tetrofosmin images (cen-
ter) and positron emission tomography
with 18F-fluorodeoxyglucose (right). (B)
Reconstructed transmission images of the
patient.
Table 1. Percentage of Viable Myocardium in Relation to
99mTc-Tetrofosmin Activity (Number of Segments)
Threshold for FDG PET FDG 50% FDG 60%
NC 99mTc-tetrofosmin activity
Preserved ($70%) 100% (81/81) 99% (80/81)
Mildly reduced (50%–70%) 94% (81/86) 88% (76/86)
Severely reduced (30%–50%) 89% (39/44) 59% (26/44)
Absent (,30%) 0% (0/5) 0% (0/5)
AC 99mTc-tetrofosmin activity
Preserved ($70%) 100% (105/105) 100% (105/105)
Mildly reduced (50%–70%) 99% (77/78) 86% (67/78)
Severely reduced (30%–50%) 70% (19/27) 37% (10/27)
Absent (,30%) 0% (0/6) 0% (0/6)
NC 5 non–attenuation-corrected image. The parentheses indicate the
number of PET viable segments/the number of all segments eligible for that
category according to 99mTc-tetrofosmin activity. AC 5 attenuation-corrected
image; FDG 5 18F-fluorodeoxyglucose.
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motion, 76 segments in 19 patients were hypokinetic, 75
segments in 21 patients akinetic and 15 segments in 6 patients
were dyskinetic by contrast or radionuclide left ventriculogra-
phy. All patients had at least one dysfunctional myocardial
segment.
Figure 3 shows the same comparisons as in Figure 2 for 166
asynergic segments. Similar to the results from all 216 seg-
ments, the percentage of concordant segments of viability
between 99mTc-tetrofosmin SPECT and FDG PET increased
from 74.2% 6 20.5% on the NC images to 88.7% 6 13.7% on
the AC images (p 5 0.005) using a 50% threshold for viability
by FDG PET. The percentage of 99mTc-tetrofosmin defect
segments within viable segments decreased from 24.5% 6
21.4% on the NC images to 13.7% 6 22.2% on the AC images
(p 5 0.036). The percentage of 99mTc-tetrofosmin uptake
segments within PET nonviable segments tended to decrease
from 35.2% 6 44.5% on the NC images to 3.7% 6 11.0% on
the AC images, but did not reach statistical significance (p 5
0.066). Using a 60% threshold for viability by FDG PET, the
percentage of concordant segments between 99mTc-
tetrofosmin and FDG again increased from 77.9% 6 18.5% on
the NC images to 89.3% 6 14.6% on the AC images (p 5
0.035). The percentage of 99mTc-tetrofosmin defect segments
within viable segments decreased from 18.2% 6 19.9% on the
NC images to 6.7% 6 10.2% on the AC images (p 5 0.010).
The percentages of 99mTc-tetrofosmin uptake segments within
PET nonviable segments did not differ significantly between
the NC and AC images (41.0% 6 41.4% vs. 25.6% 6 34.3%,
respectively, p 5 0.357). Thus, when only the segments with
wall motion abnormality were considered, attenuation correc-
tion again improved the concordance of viability between
99mTc-tetrofosmin and FDG, and decreased the underestima-
tion of viability by 99mTc-tetrofosmin.
Regional analysis. Because the effect of attenuation cor-
rection varies from region to region as demonstrated by Ficaro
et al. (25,31), we separately assessed the effect of attenuation
correction in two different myocardial regions: the inferior-
septal region, where attenuation artifacts are most likely to
occur, and the anterior-lateral region, which includes the apex.
Anterior-lateral region. Figure 4A shows the percentages of
concordant segments regarding viability between 99mTc-
tetrofosmin SPECT and FDG PET, the percentages of 99mTc-
tetrofosmin defect segments within PET viable segments and
the percentages of 99mTc-tetrofosmin uptake segments within
PET nonviable segments in the anterior-lateral region. Using a
50% threshold for viability by FDG PET, the percentages of
concordant segments of viability between 99mTc-tetrofosmin
and FDG were similar between the NC and AC images
(86.7% 6 14.0% vs. 87.5% 6 16.5%, respectively, p 5 0.796).
The percentages of 99mTc-tetrofosmin defect segments within
viable segments were also similar between the NC and AC
images (10.4% 6 13.6% vs. 12.1% 6 17.4%, respectively, p 5
0.582). The percentages of 99mTc-tetrofosmin uptake segments
within PET nonviable segments tended to decrease from
44.5% 6 50.2% on the NC images to 5.5% 6 13.5% on the AC
images, but did not differ significantly (p 5 0.102) because only
six patients had PET nonviable segments in the anterior-lateral
region. Using a 60% threshold for viability by FDG PET, the
Figure 2. Bar charts showing the percentage of concordant segments
regarding viability between 99mTc-tetrofosmin SPECT and FDG PET
(labeled as Concordance), the percentage of 99mTc-tetrofosmin defect
segments (,50% of peak activity) within viable segments by FDG PET
(labeled as TDV) and the percentage of 99mTc-tetrofosmin uptake
segments ($50% of peak) within nonviable segments (labeled as
TUNV) from all 216 segments. Data using a 50% threshold cutoff to
define viability by FDG PET are illustrated on the left, and those using
a 60% threshold cutoff are on the right. Values are calculated on the
patient basis and are expressed as mean 6 SD. NC 5 non–attenuation-
corrected image; AC 5 attenuation-corrected image; n 5 the number
of patients who were eligible for the analysis.
Figure 3. Bar charts showing the percentage of concordant segments
regarding viability between 99mTc-tetrofosmin SPECT and FDG PET
(labeled as Concordance), the percentage of 99mTc-tetrofosmin defect
segments (,50% of peak activity) within viable segments by FDG PET
(labeled as TDV) and the percentage of 99mTc-tetrofosmin uptake
segments ($50% of peak) within nonviable segments (labeled as
TUNV) from 166 asynergic segments. Data using a 50% threshold
cutoff to define viability by FDG PET are illustrated on the left, and
those using a 60% threshold cutoff are on the right. Values are
calculated on the patient basis, and are expressed as mean 6 SD.
NC 5 non–attenuation-corrected image; AC 5 attenuation corrected
image; n 5 the number of patients who were eligible for the analysis.
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percentages of concordant segments of viability between
99mTc-tetrofosmin and FDG were again similar between the
NC and AC images (85.0% 6 14.7% vs. 87.5% 6 14.2%,
respectively, p 5 0.366). The percentages of 99mTc-tetrofosmin
defect segments within viable segments were also similar
between the NC and AC images (7.5% 6 12.9% vs. 9.4% 6
13.3%, respectively, p 5 0.380). The percentage of 99mTc-
tetrofosmin uptake segments within PET nonviable segments
decreased from 62.5% 6 36.5% on the NC images to 18.8% 6
27.4% on the AC images, but did not reach statistical signifi-
cance (p 5 0.056) because only eight patients had PET
nonviable segments in this region. Thus, the effect of attenu-
ation correction was not significant in the anterior-lateral
region, although there was a trend toward improved overesti-
mation of viable myocardium by 99mTc-tetrofosmin.
Inferior-septal region. Figure 4B illustrates the same com-
parisons for the inferior-septal region. Using a 50% threshold
for viability by FDG PET, the percentage of concordant
segments of viability between 99mTc-tetrofosmin and FDG
significantly increased from 70.8% 6 24.1% on the NC images
to 94.8% 6 12.7% on the AC images (p , 0.001). The
percentage of 99mTc-tetrofosmin defect segments within viable
segments decreased from 29.5% 6 26.5% on the NC images to
5.9% 6 13.9% on the AC images (p 5 0.001). The percentages
of 99mTc-tetrofosmin uptake segments within PET nonviable
segments did not differ significantly between the NC and AC
images (12.5% 6 25.0% vs. 0.0% 6 0.0%, respectively, p 5
0.317). When a 60% threshold cutoff was used to define
viability by FDG PET, the percentage of concordant segments
of viability between 99mTc-tetrofosmin and FDG again in-
creased from 80.2% 6 20.8% on the NC images to 93.8% 6
16.9% on the AC images (p 5 0.028). The percentage of
99mTc-tetrofosmin defect segments within viable segments
decreased from 19.1% 6 22.6% on the NC images to 0.0% 6
0.0% on the AC images (p 5 0.002). The percentage of
99mTc-tetrofosmin uptake segments within PET nonviable
segments on the NC images (12.5% 6 23.1%) appeared to be
lower than that on the NC images (35.4% 6 44.0%), but was
not significantly different (p 5 0.269). Thus, attenuation cor-
rection improved the concordance of viability between 99mTc-
tetrofosmin and FDG, and decreased the underestimation of
viability by 99mTc-tetrofosmin in the inferior-septal region.
Discussion
This study describes for the first time the utility of attenu-
ation correction for assessing myocardial viability with SPECT
imaging. The major findings of this study were as follows: 1)
attenuation correction increased the percentage of concordant
segments regarding viability between 99mTc-tetrofosmin
SPECT and FDG PET, and decreased the underestimation of
viability by 99mTc-tetrofosmin; 2) when the LV myocardium
was divided into two regions, only the inferior-septal region
showed such improvements, while the anterior-lateral region
did not.
99mTc-tetrofosmin as a myocardial viability marker.
Technetium-99m-tetrofosmin is a newly introduced cationic
lipophilic 99mTc-labeled myocardial perfusion tracer as an
alternative to 201Tl (12). This agent reportedly has good
diagnostic accuracy for detection of CAD when compared with
201Tl (32). It has been shown that the uptake and retention of
this tracer depend on cellular metabolism (33), suggesting that
cellular viability may be essential for its uptake and retention.
A recent animal study has also demonstrated that myocardial
99mTc-tetrofosmin uptake is affected not only by flow but also
by viability (34). In clinical studies, it has been reported that
regional resting 99mTc-tetrofosmin activity closely correlates
Figure 4. Bar charts showing the percentage of concordant segments
regarding viability between 99mTc-tetrofosmin SPECT and FDG PET
(labeled as Concordance), the percentage of 99mTc-tetrofosmin defect
segments (,50% of peak activity) within viable segments by FDG PET
(labeled as TDV) and the percentage of 99mTc-tetrofosmin uptake
segments ($50% of peak) within nonviable segments (labeled as
TUNV) in the anterior-lateral (A) and inferior-septal regions (B).
Data using a 50% threshold cutoff to define viability by FDG PET are
illustrated on the left, and those using a 60% threshold cutoff are on
the right. Values are calculated on the patient basis, and are expressed
as mean 6 SD. NC 5 non–attenuation-corrected image; AC 5
attenuation corrected image; n 5 the number of patients who were
eligible for the analysis.
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with regional reinjection 201Tl activity (15), and that defect size
on resting 99mTc-tetrofosmin images is similar to that on
reinjection 201Tl images (35), suggesting the potential utility of
this tracer as a myocardial viability marker. In another study,
using a quantitative approach and receiver operating charac-
teristic analysis, rest 99mTc-tetrofosmin and rest-redistribution
201Tl imaging were found to be comparable in predicting
functional recovery after revascularization (18). To date, how-
ever, the direct comparison of 99mTc-tetrofosmin activity with
metabolic activity as measured by FDG PET has not yet been
reported.
Effect of attenuation correction. The present data indicate
that none of the segments with absent 99mTc-tetrofosmin
uptake (,30% of peak activity) on both NC and AC images
showed evidence of tissue viability by PET. In contrast, most of
the segments with preserved 99mTc-tetrofosmin activity ($70%
of peak) were viable. This observation suggests that the
determination of myocardial viability may not be difficult in
these extreme categories regardless of whether attenuation
correction is used. On the other hand, the segments with mildly
to severely reduced 99mTc-tetrofosmin activity (30% to 70% of
peak) showed various patterns of viability.
We observed that a considerable portion (14.1% to 19.8%)
of PET viable segments had 99mTc-tetrofosmin defects (de-
fined as ,50% of peak) on the conventional NC images,
indicating that the NC 99mTc-tetrofosmin images underesti-
mate tissue viability compared to FDG PET. This is in
agreement with published data comparing 99mTc-sestamibi
SPECT with FDG PET (14,21,22). Sawada et al. (21) and
Altehoefer et al. (19) observed metabolic activity within 99mTc-
sestamibi defects and concluded that 99mTc-sestamibi uptake
may underestimate the presence of viable myocardium. Dilsi-
zian et al. (14) reported high agreement for viability between
reinjection 201Tl and 99mTc-sestamibi imaging using quantita-
tive analysis, but underestimation of viable myocardium still
occurred in 4 of 18 regions (22%) with irreversible 99mTc-
sestamibi defects (,50% of peak activity). More recently,
Soufer et al. (22) have demonstrated that such underestima-
tion of viable myocardium was predominantly observed in the
inferior region, where attenuation artifacts are likely to occur.
It is well recognized that attenuation artifacts may unfavorably
affect the quantification of regional tracer activity on conven-
tional SPECT images. Our data indicate that the AC images
increase the concordance of viability between 99mTc-
tetrofosmin SPECT and FDG PET, and decrease the under-
estimation of viable myocardium, which may partially explain
the underestimation of viable myocardium with 99mTc-
sestamibi observed in the previous studies. When two myocar-
dial regions (i.e., the anterior-lateral region and inferior-septal
region) were separately analyzed, only the inferior-septal re-
gion showed such significant improvements while the anterior-
lateral region did not. Thus, the benefit of attenuation correc-
tion appears to be the improved underestimation of viability,
particularly in the inferior-septal region, resulting in the im-
proved overall concordance of viability between 99mTc-
tetrofosmin SPECT and FDG PET. It should also be noted,
however, that even AC images may still underestimate and/or
overestimate tissue viability as compared to FDG PET.
Although the previous studies have mainly focused on
underestimation of viable myocardium using SPECT imaging
and 99mTc perfusion tracers, an overestimation of viability may
also occur in the clinical setting. Soufer et al. (22) reported that
such overestimation of viability by 99mTc-sestamibi imaging
predominantly occurred in the apex, which is consistent with
our results that, on the NC images, the percentage of 99mTc-
tetrofosmin uptake segments within nonviable segments was
relatively high in the anterior-lateral region (Fig. 4A). It was
not clear from the current data whether attenuation correction
would improve such overestimation of viable myocardium by
99mTc-tetrofosmin SPECT imaging, although there was a trend
toward improved overestimation of viability. This was partially
because only limited number of patients had nonviable seg-
ments based on FDG activity, despite the severe CAD in our
study population as evidenced by the low LVEF (30% 6 11%)
and high prevalence of multivessel disease. However, this
reflects the fact that even in patients with severe CAD, the
majority of dysfunctional myocardium is metabolically active as
measured by FDG PET. In a study by Baer et al. (29), for
example, 30 of 42 patients (71%) had FDG activity in their
severely dysfunctional and infarct regions. A further study
specifically involving patients with a large amount of nonviable
myocardium may be necessary to address this issue.
Clinical implications. We are aware that perfusion imag-
ing alone, in the absence of metabolic information, may not
completely resolve the challenging issue of myocardial viability
even when attenuation correction is performed. Recent PET
studies using flow tracer have shown that perfusion imaging
with attenuation correction alone may have a limited value in
predicting functional recovery after revascularization (6,36).
Although the preserved myocardial perfusion is certainly an
important factor for maintaining tissue viability as demon-
strated in this study and in others (37,38), it may not neces-
sarily imply the presence of ischemically compromised but
viable myocardium. Considering the wide availability of
SPECT techniques as compared to PET, and the increasing
interest in the potential use of 99mTc-based tracers as a viability
marker (13,16,17,39–41), however, it is important to develop
and evaluate newer SPECT techniques using 99mTc agents for
the detection of viable myocardium. It is also noteworthy that
previous viability studies have often pointed out that attenua-
tion artifacts may unfavorably affect the diagnostic accuracy of
viability tests using conventional SPECT techniques
(14,16,17,19,22,42). In this regard, the results of the current
study indicate that attenuation correction represents a useful
improvement in the detection of viable myocardium using a
quantitative approach and SPECT imaging.
Study limitations. We directly compared AC and NC
99mTc-tetrofosmin activity using FDG PET as the reference
standard; functional outcome data after revascularization were
not obtained. Thus, although numerous studies have demon-
strated that preserved metabolic activity measured by FDG
PET is an accurate maker of tissue viability (2,4,29,30,42),
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definitive statements regarding the use of AC 99mTc-
tetrofosmin SPECT in the management of patients with LV
dysfunction are not possible based on the current data. The
purpose of this study was, however, to investigate the effect of
attenuation correction on myocardial 99mTc-tetrofosmin
SPECT for assessing viability using FDG as a biological
marker of tissue viability. Further prospective studies involving
patients undergoing revascularization are required to deter-
mine the clinical significance of AC 99mTc-tetrofosmin SPECT
imaging.
We did not perform scatter correction in this study. As
described by Ficaro et al. (25) and by our previous study (26),
attenuation correction may amplify the scatter spillover into
nearby myocardium, typically the inferior-septal wall, from
splanchnic activity. Therefore, it is anticipated that the addi-
tional use of scatter correction combined with attenuation
correction could have further improved the detection of viable
myocardium. However, there are no methods for simultaneous
attenuation/scatter correction currently available for clinical
use. Further work on instrumentation should aim for the
incorporation of scatter correction into attenuation correction.
Conclusions. Our data indicate that AC resting 99mTc-
tetrofosmin myocardial SPECT improves the detection of
viable myocardium mainly by decreasing the underestimation
of viability in the inferior-septal region. The AC 99mTc-
tetrofosmin SPECT may, however, still underestimate and/or
overestimate myocardial viability compared to FDG PET.
Further work should be directed toward the incorporation of
scatter correction into attenuation correction.
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